CytoSorbents Q3 Revenue Rises 3% as Operating Cash Flow Reaches Breakeven

CytoSorbents reported third-quarter 2026 revenue of $9.7 million, up 3% year over year, and a net loss of $1.8 million. Gross margin increased to 75%, while the operating loss narrowed to $1.2 million. The company also reported positive operating cash flow of approximately $43,000, excluding restru…